ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

IBI356

A development code. Also written as “IBI356 for MAD” and “IBI356 for SAD”.

Its studies are mostly in Dermatitis, Atopic, led by Innovent Biologics.

Furthest: phase 2, since Dec 15, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics20 open or runningphase 2since Dec 15, 2025Dec 12, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT06193434 · 99 enrolled · China
  2. Dec 15, 2025Phase 2 study in Dermatitis, AtopicPhase 2 reachedNCT07330934 · 18 enrolled · China
  3. Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT07330934 · “Sponsor Decision”

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07330934Dermatitis, Atopic · China2TerminatedAug 18, 202618
NCT06193434Healthy Participants · China1CompletedAug 20, 202599

How it is read

Names in the registry

  • “IBI356”, 1 entry
  • “IBI356 for MAD”, 1 entry
  • “IBI356 for SAD”, 1 entry

Codes read as this program: IBI356.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.